Oarsman Capital Inc. Invests $253,000 in IDEXX Laboratories, Inc. $IDXX

Oarsman Capital Inc. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 472 shares of the company’s stock, valued at approximately $253,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mutual of America Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 79.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after purchasing an additional 8,609 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after acquiring an additional 113 shares during the last quarter. Plato Investment Management Ltd lifted its holdings in IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after acquiring an additional 835 shares during the last quarter. Genesis Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $215,000. Finally, ORG Wealth Partners LLC acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $273,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the sale, the executive vice president owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the sale, the director directly owned 262 shares in the company, valued at $169,600.46. This represents a 89.30% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 54,057 shares of company stock valued at $34,293,468. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 1.1%

NASDAQ:IDXX opened at $627.66 on Thursday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock’s fifty day moving average is $638.30 and its two-hundred day moving average is $565.46. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The stock has a market capitalization of $50.21 billion, a price-to-earnings ratio of 52.26, a price-to-earnings-growth ratio of 4.11 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the firm earned $2.44 earnings per share. The firm’s revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on IDXX. UBS Group began coverage on IDEXX Laboratories in a report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price objective on the stock. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. BTIG Research upped their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Finally, JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.